

Special Issue

Immunity at the Gate of Entrance; Vaccines against Respiratory Viruses such as Influenza, Corona, and RSV 2.0

Message from the Guest Editor

Most vaccines induce systemic immunity through intramuscular administration. This route of vaccination disregards a very potent part of the immune system—local adaptive immunity. Challenges include adjuvation, formulation, and induction of long-lasting immunity. For influenza (and possibly SARS-CoV-2) in particular, a broadly reactive immunity is a challenge, and Trm and local stem antibodies may be an answer. For corona, RSV, and influenza immunity, longevity is a holy grail. Therefore, research that provides insight into local immune parameters that correlate with protection against respiratory viruses or that are shown to be long-lasting is welcomed. Immune induction may be through vaccination, using adjuvants and formulation techniques to steer the immune response or by immune transfer techniques, etc. when this leads to a better understanding of potent vaccine targets. Combining insights and strategies developed for different respiratory viruses into one Special Issue encourages cross-pollination of the different research fields and would advance the development of locally administered respiratory vaccines overall.

Guest Editor

Dr. Jorgen De Jonge

Department for Immune Mechanisms, Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Deadline for manuscript submissions

closed (15 October 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/80413

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).